Newsfeeds - Spark Newswire

1 minute read

Why Icosavax Stock Is Skyrocketing Today

Today, 9:39 AM

Icosavax Inc (NASDAQ: ICVX) shares are trading higher by 45.63% to $12.99 Thursday morning on continued strength after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus.

ICVX

1 minute read

RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday

By Lisa Levin

Today, 9:39 AM

U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session.

ABCL

3 minute read

Dow Tumbles Over 500 Points; ECB Raises Rates By 50 bps

By Lisa Levin

Today, 9:39 AM

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 500 points after the Federal Reserve raised interest rates by 50 bps on Wednesday.

AZRE

2 minute read

Peering Into Icosavax’s Recent Short Interest

By Benzinga Insights

Today, 9:39 AM

Icosavax's (NASDAQ:ICVX) short percent of float has fallen 12.27% since its last report. The company recently reported that it has 490 thousand shares sold short, which is 1.93% of all regular shares that are available for trading.

ICVX

3 minute read

Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket

By Lisa Levin

Today, 9:39 AM

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday.

ABCL

3 minute read

Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps

By Lisa Levin

Today, 9:39 AM

U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision.

1 minute read

Comparing With Pfizer’s Vaccine, Icosavax RSV Candidate ‘Could Establish Differentiation,’ Analyst Says

By Vandana Singh

Today, 9:39 AM

Icosavax Inc (NASDAQ:ICVX) provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV), demonstrating…

GSK

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 9:39 AM

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) stock increased by 137.8% to $0.6 during Wednesday’s regular session. Trading volume for Vallon…

ACON

1 minute read

Icosavax Highlights Six Months Durability Data For Respiratory Syncytial Virus Vaccine Candidate

By Vandana Singh

Today, 9:39 AM

Icosavax Inc (NASDAQ:ICVX) provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These…

ICVX

1 minute read

Icosavax Provides Six-Month Update From Phase 1/1b Trial Of IVX-121

By Bill Haddad

Today, 9:39 AM

- In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older

ICVX